I'm not at #ASCO23, but Ryan Cross the Science Boss Max Gelman + Lei Lei Wu are representing Endpoints News. On Monday, they'll have an amazing virtual lineup of experts talking about the latest research from the meeting: asco23.endpts.com

More than 400 Grail patients incorrectly told they may have cancer: prompting insurers to pause or review relationship with the US biotech Financial Times scoop ft.com/content/b91fc9…

Breaking: Merck sues US government over IRA, challenging drug pricing bill’s constitutionality Becomes the first drug company to bring the industry's furor over the IRA into the courtroom: endpts.com/merck-sues-us-…

EXCLUSIVE from me: Illumina CEO Francis deSouza has resigned, just weeks after activist investor Carl Icahn waged an unsuccessful battle to remove him from the board Endpoints News endpts.com/exclusive-illu…

After early signs of success in its lead rare disease program, Moderna CEO Bancel told me his company is doubling down on #mRNA therapies for rare diseases (focused on liver) and looking at getting into N-of-1 therapies too. My in-depth story Endpoints News: endpts.com/moderna-makes-…

The FDA's rejection of Intercept's NASH drug may not have been a surprise, but the company's decision to pivot out of the NASH space altogether certainly is. More from Nicole DeFeudis: endpts.com/intercept-nash…

Big news for Alzheimer's patients: “It’s not going to be the cure-all, but it can be a very meaningful adjunct to the treatment of some people,” Alvaro Pascual-Leone, a professor of neurology at Harvard Medical School, told Ryan Cross the Science Boss. endpts.com/alzheimers-dru…

We've got some exciting news here at Endpoints News. The one and only Lia DeGroot is joining us to help cover the FDA! She'll be teaming up with Zach Brennan to keep our readers updated on the regulatory and legislative world, part of our push to expand our DC presence.

Our #WIB23 event is tomorrow! Join us for a celebration of our 20 honorees, plus panels with AbbVie's Azurii Collier, Iolyx Therapeutics' Elizabeth Jeffords, Ventyx, ADARx, and ImmPACT's Sheila Gujrathi and NIBR's Fiona Marshall, hosted by Amber Tong and me. womeninbio23.endpts.com

We got more details on the damaged Pfizer plant in North Carolina after Wednesday's tornado. → plant is still closed → the warehouse had the most damage Read more from Tyler Patchen & Lia DeGroot endpts.com/damaged-pfizer…

!!!

I may still be in my very first week at Endpoints News but I already have my first big assignment: I'm in need of a ~ breaking news reporter ~ to help build up our health tech coverage! Are you obsessed (or at least curious) about how tech is changing healthcare? DM me!

We now know what 10 drugs will be up for price negotiation. Most of the medications to end up on the list were expected (ie, Eliquis) but the inclusion of Novo Nordisk's Fiasp and NovoLog was a surprise endpts.com/us-selects-fir…

A must-read look into the turnaround story for antibody-drug conjugates on the heels of two major deals: endpts.com/decade-of-the-…

📢I’m ~psyched~ to share that Nicole Wetsman is joining Endpoints News as our new deputy editor for events and special projects. She’s an important part of our growth, and a statement of how we think events should be done in specialty media. 1/

As ivermectin moves back into the news cycle, my story tracing the faulty science that led to the idea the drug successfully treats Covid: marketwatch.com/story/you-will…

This is a travesty. #IStandWithEvan #JournalismIsNotACrime wsj.com/world/russia/e… via The Wall Street Journal

So excited that Alexis Kramer has joined Endpoints News to steer our pharma coverage! She has a decade of experience covering law at Bloomberg Law, including working on stories about how various Trump drug pricing regulations were challenged in court. talkingbiznews.com/media-news/end…